FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BELANOFF JOSEPH K</u>						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]									ck all app			erson(s) to l	
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 275 MIDDLEFIELD ROAD					02/	3. Date of Earliest Transaction (Month/Day/Year) 02/18/2005									X Officer (give title Other (specify below) Chief Executive Officer				
(Street) MENLO PARK CA 94025					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	ndividual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5		Zip)	on-Deriv	ative	Sec	uritie		auirea	l Di	sposed o	of or F	enefic	ılleir	Own	2d			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day				tion	on 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock 02/18/2					2005	005			S ⁽²⁾		2,500	D	\$4.4	1948	2,366,695			D	
Common Stock															300,000			I	Custodian for minor son ⁽¹⁾
Common Stock															300,000			I	Custodian for minor daughter ⁽¹⁾
Common Stock 02/22/20					2005				S ⁽²⁾		2,500	D	\$4	.47	2,364,195		D		
		Та	ble II -								osed of, convertib				wned				
Derivative Conversion Date Security or Exercise (Month/Day/Year)			if any	med on Date,	4. Transa Code (8)	ction	5. Number of			Exercion Da	risable and	7. Title and Amount of Securities Underlying Derivative Security (Instrand 4)		8. De Se (In	rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	of Shares						

Explanation of Responses:

- 1. The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
- 2. The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.

s/s Fred Kurland, CFO of **Corcept Therapeutics** Incorporated attorney-in-fact

02/23/2005

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.